Suppr超能文献

真实世界数据中小细胞肺癌术后意外发现长期结果。

Long-term results of postoperative unsuspected small cell lung cancer on real-world data.

机构信息

Department of Thoracic Surgery, The First Medical Center, The Chinese PLA General Hospital, Beijing, People's Republic of China.

Department of Thoracic Surgery, The Hainan Hospital, The Chinese PLA General Hospital, Sanya, Hainan Province, People's Republic of China.

出版信息

BMC Cancer. 2022 Dec 2;22(1):1256. doi: 10.1186/s12885-022-10341-9.

Abstract

BACKGROUND

In traditional opinion, solid pulmonary nodule suspected lung cancer should be confirmed by pathology before the operation to exclude small cell lung cancer (SCLC), considering SCLC tends to be aggressive and surgical effect in the management of SCLC remains controversial. The aim of this study was to evaluate the survival result and risk factors of postoperative unsuspected SCLC.

METHODS

A total of 120 patients with postoperative unsuspected SCLC who were confirmed by pathology and referred to Chinese PLA General Hospital between 2000 and 2021 were retrospectively analyzed (surgery group). Additionally, 120 patients with limited-stage SCLC who underwent chemotherapy and radiotherapy in the same period were enrolled in the chemoradiotherapy group.. Kaplan-Meier method was used to estimate survival; the Log-Rank test was used to compare survival rates between different groups; a COX stepwise regression model was used for multivariate analysis.

RESULTS

Among 120 patients in the surgery group, 28 were with central type and other 92 with peripheral type. The median survival (OS) was 44.85 months, and the 5-year survival rate was 46%. The 5-year survival rates for stage I, II, and III were 52.1%, 45.4%, and 27.8%, respectively. The mean disease-free survival time (DFS) was 30.63 ± 4.38 months, and the 5-year DFS rate was 31.5%. In the chemoradiotherapy group, the mean OS was 21.4 ± 4.26 months, and the 5-year survival rate was 28.3%. The 5-year survival rates for clinical stage I, II, and III were 42.5%, 39.8%, and 20.5%, respectively. The mean progression-free survival (PFS) was 10.63 ± 3.6 months. In the surgery group, one-way ANOVA revealed that the gender, symptoms, smoking history, tumor location, and postoperative radiotherapy were not associated with OS (P ≥ 0.05), while age, surgical approach, surgical method, N stage, TNM stage, and vascular tumor thrombus were related to OS (P < 0.05). Multivariate analysis indicated that the N stage was associated with OS (HR = 1.86 P = 0.042).

CONCLUSION

Surgery and adjuvant therapy were found to have encouraging outcomes in postoperative unsuspected SCLC. Patients with stage I, stage II and part of stage IIIA SCLC could benefit from surgery and the standard lobectomy, and systematic lymph node dissection, is also recommended for these patients.

摘要

背景

传统观点认为,疑似肺癌的肺部实性结节应通过病理检查确认,以排除小细胞肺癌(SCLC),因为 SCLC 往往具有侵袭性,且 SCLC 的手术效果仍存在争议。本研究旨在评估术后未发现 SCLC 的生存结果和危险因素。

方法

回顾性分析 2000 年至 2021 年期间因术后病理证实为 SCLC 而转诊至中国人民解放军总医院的 120 例患者(手术组)。此外,还纳入了同期接受化疗和放疗的局限期 SCLC 患者 120 例(化疗组)。采用 Kaplan-Meier 法估计生存情况;采用 Log-Rank 检验比较不同组之间的生存率;采用 COX 逐步回归模型进行多因素分析。

结果

手术组 120 例患者中,中央型 28 例,周围型 92 例。中位总生存(OS)时间为 44.85 个月,5 年生存率为 46%。Ⅰ期、Ⅱ期和Ⅲ期的 5 年生存率分别为 52.1%、45.4%和 27.8%。无病生存时间(DFS)的平均时间为 30.63±4.38 个月,5 年 DFS 率为 31.5%。化疗组 OS 的平均时间为 21.4±4.26 个月,5 年生存率为 28.3%。Ⅰ期、Ⅱ期和Ⅲ期的 5 年生存率分别为 42.5%、39.8%和 20.5%。中位无进展生存(PFS)时间为 10.63±3.6 个月。在手术组中,单因素方差分析显示,性别、症状、吸烟史、肿瘤部位和术后放疗与 OS 无关(P≥0.05),而年龄、手术方式、手术方法、N 分期、TNM 分期和脉管瘤栓与 OS 相关(P<0.05)。多因素分析表明,N 分期与 OS 相关(HR=1.86,P=0.042)。

结论

手术和辅助治疗在术后未发现 SCLC 中显示出令人鼓舞的结果。Ⅰ期、Ⅱ期和部分ⅢA 期 SCLC 患者可从手术中获益,建议对这些患者进行标准的肺叶切除术和系统淋巴结清扫术。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4443/9719118/f32cf0e7996b/12885_2022_10341_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验